NCT04849013 - Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2023

Conditions

Healthy

Interventions

DRUG

Placebo

Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs

DRUG

Mescaline 100mg

"Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

DRUG

Mescaline 200mg

"Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

DRUG

Mescaline 400mg

"Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

DRUG

Mescaline 800mg

"Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

DRUG

Mescaline 800mg + Ketanserin 40mg

"Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose"

Trial Locations (1)

4056

University Hospital Basel, Clinical Trial Unit, Basel

All Listed Sponsors

lead

University Hospital, Basel, Switzerland

OTHER